NOK 2.59
(15.42%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 2.11 Billion USD | -3.09% |
2022 | 2.18 Billion USD | -6.83% |
2021 | 2.34 Billion USD | 18.9% |
2020 | 1.96 Billion USD | 571.33% |
2019 | 293.37 Million NOK | 91.32% |
2018 | 153.33 Million NOK | -28.5% |
2017 | 214.46 Million NOK | -14.9% |
2016 | 252 Million NOK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 179.87 Million USD | -6.26% |
2024 Q1 | 2.08 Billion USD | -7.83% |
2023 FY | 2.11 Billion USD | -3.09% |
2023 Q4 | 2.11 Billion USD | 13.88% |
2023 Q3 | 1.85 Billion USD | -8.24% |
2023 Q2 | 2.02 Billion USD | -5.89% |
2023 Q1 | 2.14 Billion USD | -1.46% |
2022 Q3 | 2.48 Billion NOK | 5.44% |
2022 Q4 | 2.18 Billion USD | -12.31% |
2022 Q2 | 2.35 Billion NOK | 6.21% |
2022 Q1 | 2.22 Billion NOK | -5.13% |
2021 Q4 | 2.34 Billion NOK | 32.38% |
2021 Q3 | 1.76 Billion NOK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Arctic Bioscience AS | 300.25 Million NOK | -604.164% |
Aqua Bio Technology ASA | 34.42 Million NOK | -6040.851% |
ArcticZymes Technologies ASA | 339.32 Million NOK | -523.083% |
BerGenBio ASA | 174.33 Million NOK | -1112.76% |
Hofseth BioCare ASA | 390.11 Million NOK | -441.954% |
PCI Biotech Holding ASA | 44.05 Million NOK | -4699.692% |
Thor Medical ASA | 330.83 Million NOK | -539.069% |
Ultimovacs ASA | 349.03 Million NOK | -505.739% |